ANDA 214292, held by Amneal Pharms. Ethinyl Estradiol; Norethindrone Acetate.
As of Nov 16, 2026, ANDA 214292 (Norethindrone Acetate And Ethinyl Estradiol And Ferrous Fumarate), held by Amneal Pharms, was first approved by FDA on Jul 20, 2021, with 2 approved supplements and 0 published complete response letters.
Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules are indicated for use by females of reproductive age to prevent pregnancy. The efficacy of norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules in women with a body mass index (BMI) of more than 35 kg/m 2 has not been evaluated.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 20, 2021 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Norethindrone Acetate And Ethinyl Estradiol And Ferrous Fumarate0.02MG;1MG · capsule;oral | Ethinyl Estradiol; Norethindrone Acetate | Discontinued |
| Sep 28, 2023 | Supplement 5Labeling · Standard review | Approved | None posted |
| Sep 28, 2023 | Supplement 12Labeling · Standard review | Approved | None posted |
| Jul 20, 2021 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters